Abbott snags CE mark for diabetes monitor

Abbott Laboratories ($ABT) won a CE mark for its FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System, expanding its presence on the European diabetes market with a next-gen device. The latest FreeStyle system allows physicians to program insulin dosage plans into the meter, ideally boosting patient adherence, the company said. Abbott plans to launch the device around the continent in the coming weeks. More

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.